Advanced in Ewing Sarcoma

Dr. Sue S. Yom

Radiation Oncology
University Of California San Francisco
2330 Post St, 
San Francisco, CA 
 (2527.0 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Advanced in Ewing Sarcoma
University Of California San Francisco
2330 Post St, 
San Francisco, CA 
 (2527.0 mi)
OverviewInsuranceLocationsClinical Research

Overview

Sue Yom is a Radiation Oncologist in San Francisco, California. Dr. Yom and is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Nasopharyngeal Carcinoma, Olfactory Neuroblastoma, Merkel Cell Carcinoma, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Her clinical research consists of co-authoring 253 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in TX
Hospital Affiliations
Ucsf Medical Center
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

UNIVERSITY OF CALIFORNIA SAN FRANCISCO
2330 Post St, San Francisco, CA 94115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Other, Procedure, Drug, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
Enrollment Status: Recruiting
Publish Date: January 30, 2025
Intervention Type: Drug, Radiation
Study Drugs: NBTXR3, Cetuximab
Study Phase: Phase 3
Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers
Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers
Enrollment Status: Completed
Publish Date: February 20, 2025
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer With Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study With Correlative Biomarkers
PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer With Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study With Correlative Biomarkers
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Radiation, Procedure, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2024
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 08, 2024
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
Enrollment Status: Completed
Publish Date: March 15, 2023
Intervention Type: Drug, Radiation
Study Drugs: BMX-001, Cisplatin
Study Phase: Phase 1/Phase 2
A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck
A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: May 03, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 10 Less Clinical Trials

253 Total Publications

Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 22, 2025
Similar Doctors
Advanced in Ewing Sarcoma
Dr. Scott G. Soltys
Radiation Oncology
Advanced in Ewing Sarcoma
Dr. Scott G. Soltys
Radiation Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.3 mi)
650-723-4000
Languages Spoken:
English
Offers Telehealth

Scott Soltys is a Radiation Oncologist in Stanford, California. Dr. Soltys and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Meningioma, Astrocytoma, Acoustic Neuroma, Brain Tumor, and Rhizotomy.

Advanced in Ewing Sarcoma
Dr. Michael F. Gensheimer
Radiation Oncology
Advanced in Ewing Sarcoma
Dr. Michael F. Gensheimer
Radiation Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.3 mi)
650-723-4000
Experience:
15+ years
Languages Spoken:
English
Offers Telehealth

Michael Gensheimer is a Radiation Oncologist in Stanford, California. Dr. Gensheimer has been practicing medicine for over 15 years and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Lung Cancer, Adenoid Cystic Carcinoma, Nasopharyngeal Carcinoma, Pleuropulmonary Blastoma, and Gastrostomy.

Advanced in Ewing Sarcoma
Dr. Sarah S. Donaldson
Radiation Oncology
Advanced in Ewing Sarcoma
Dr. Sarah S. Donaldson
Radiation Oncology
300 Pasteur Dr, 
Stanford, CA 
 (28.3 mi)
650-723-4000
Languages Spoken:
English

Sarah Donaldson is a Radiation Oncologist in Stanford, California. Dr. Donaldson and is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Breast Cancer, and Hodgkin Lymphoma.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile